Rony Avritscher

Rony Avritscher is a Professor at The University of Texas MD Anderson Cancer Center, where he specializes in oncology, radiology, and radiation oncology. His research focuses on hepatocellular carcinoma, liver-directed therapies, and cancer imaging, with recent work on Yttrium-90 radioembolization for large HCC tumors and fibrolamellar variants, as well as neuroendocrine liver metastatic burden patterns and outcomes. He has published on TTI-101, a first-in-class oral STAT3 inhibitor, and synthetic tumor extracellular volume as a predictive biomarker for colorectal liver metastases. His research has been supported by a $792,000 award for imaging and modulation of the liver tumor immune environment.